Exondys51.com

Exondys51.com has server used 54.204.43.126 (United States) ping response time Hosted in Amazon Technologies Inc. Register Domain Names at CSC Corporate Domains, Inc.. This domain has been created 6 years, 117 days ago, remaining 247 days. You can check the 9 Websites and blacklist ip address on this server

Domain information

Registrar WHOIS Server: whois.corporatedomains.com

Registrar URL: http://cscdbs.com     See All 0+

Creation Date: 2015-05-29 6 years, 117 days

Updated Date: 2021-05-25 121 days ago

Expiry Date: 2022-05-29 247 days left     See All

  Sign up for notifications near expiration

Registrar: CSC Corporate Domains, Inc.

Abuse Email: [email protected]

Abuse Phone: 8887802723

  Full details

Top 10 Hosting Providers

Registrar URLDomain CountsRegistrar NameAbuse Email
www.godaddy.com2,280,668GoDaddy.com, LLC[email protected]
www.tucows.com535,579Tucows Domains Inc.
networksolutions.com526,027Network Solutions, LLC[email protected]
www.namecheap.com333,839NameCheap, Inc.[email protected]
www.enom.com299,925eNom, LLC
www.publicdomainregistry.com294,948PDR Ltd. d/b/a PublicDomainRegistry.com[email protected]
www.whois.godaddy.com174,077GoDaddy.com, LLC[email protected]
www.fastdomain.com161,753FastDomain Inc.[email protected]
www.ionos.com159,2071&1 IONOS SE[email protected]
www.networksolutions.com149,653Network Solutions, LLC[email protected]

Full view & Download

Keywords Suggestions

Exondys 51 pi

Exondys 51 cpt

Exondys 51 dmd

Exondys 51 ema

Exondys 51 cost

Exondys 51 data

Exondys 51 fda

Exondys 51 uspi

Exondys 51 label

Exondys 51 wiki

Exondys 51 dosing

Exondys 51 price

Exondys 51 vector

Exondys 51 results

Exondys 51 approval

Exondys 51 efficacy

Exondys 51 medscape

Exondys 51 scholarly

Exondys 51 wikipedia

Exondys 51 eteplirsen

Exondys 51 controversy

Exondys 51 2020 sales

Exondys 51 hcpcs code

Exondys 51 annual cost

Exondys 51 launch date

( Please select at least 2 keywords )

See More:   A   B   C   D   E   F   G   H   I   J   K   L   M   N   O   P   Q   R   S   T   U   V   W   X   Y   Z  

› Exondys 51 mechanism of action

› Exondys 51 fda approval

› Exondys 51 label

› Exondys 51 approval

› Exondys 51 wiki

› Exondys 51 price

› Eteplirsen exondys 51

› Eteplirsen

Hosting Provider

NetName: AMAZON

Organization: Amazon Technologies Inc.     See All 439,891+

Provider URL: Amazon.com

Hostname: ec2-54-204-43-126.compute-1.amazonaws.com

IP Server: 54.204.43.126 Reg: 2014-10-23, Updated: 2021-02-10

Blacklist: Check Backlist Status

Country: United States

Address: 410 Terry Ave N., Seattle, WA 98109, US

Latitude: 39.048100

Longitude: -77.472801

Name Server:

  • DNS1.EASYDNS.COM
  • DNS2.EASYDNS.NET
  • DNS3.EASYDNS.ORG
  • DNS4.EASYDNS.INFO

Abuse Email: [email protected]

Abuse Phone: +1-206-266-4064

Top 10 Hosting Providers

Website URLDomain CountsOrganizationAbuse Email
Google.com681,421Google LLC[email protected]
Godaddy.com650,706GoDaddy.com, LLC[email protected]
Cloudflare.com637,900Cloudflare, Inc.[email protected]
Endurance.com488,827The Endurance International Group, Inc.[email protected]
Amazon.com439,891Amazon Technologies Inc.[email protected]
297,405Domain Name Services
Amazonaws.com287,121Amazon Technologies Inc.[email protected]
Liquidweb.com159,971Liquid Web, L.L.C[email protected]
Squarespace.com150,667Squarespace, Inc.[email protected]
Ripe.net128,362RIPE Network Coordination Centre[email protected]

Full view & Download

List of found email addresses

No Emails Found

Find Websites hosted

1: Amondys45.com

2: Duchenne.com

3: Exondys51.com

4: Vyondys53.com

5: Technobezz.com Changed to: 104.26.9.27

6: Home.bt.com Changed to: 68.142.68.29

7: Whatismyip.com Changed to: 104.27.195.88

8: Clinicaltrials.sarepta.com

9: Limbgirdle.com

At least 9 Sites on this server

Port Scanner (IP: 54.204.43.126)

Contact Us EXONDYS 51 (eteplirsen) Injection EXONDYS 51

  • You are about to leave EXONDYS51.COM, a Sarepta website
  • You have selected to view information that is intended for US healthcare professionals only
  • By clicking “continue,” you certify that you are a US healthcare professional
  • Click "Cancel" to stay and learn more about EXONDYS 51.

Exondys51.com   DA: 17 PA: 11 MOZ Rank: 28

EXONDYS 51 (eteplirsen) Injection For Patients And

  • EXONDYS 51 is the first FDA-approved Duchenne muscular dystrophy treatment for patients who have a confirmed genetic mutation in the dystrophin gene that can be treated by skipping exon 51
  • In some patients, it helps the body make a shorter form of the dystrophin protein
  • Approved under accelerated approval
  • Accelerated approval allows for drugs to be approved based on a marker that is

Exondys51.com   DA: 17 PA: 17 MOZ Rank: 35

Learn About A Treatment Option And Clinical Study Result

  • EXONDYS 51 is a treatment for Duchenne muscular dystrophy
  • It uses a technology called exon skipping to help the body make a shorter form of the dystrophin protein
  • EXONDYS 51 is given in a once-weekly infusion.
  • EXONDYS 51 is used to treat Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation in the dystrophin gene that can be treated by

Exondys51.com   DA: 17 PA: 24 MOZ Rank: 43

Treatment Option What Is EXONDYS 51 (eteplirsen

  • You are about to leave EXONDYS51.COM, a Sarepta website
  • You have selected to view information that is intended for US healthcare professionals only
  • By clicking “continue,” you certify that you are a US healthcare professional
  • Click "Cancel" to stay and learn more about EXONDYS 51.

Exondys51.com   DA: 17 PA: 18 MOZ Rank: 38

Learn About A Treatment Option And Clinical Study Result

  • EXONDYS 51 (ETEPLIRSEN) IS DESIGNED TO SKIP EXON 51
  • EXONDYS 51 is indicated for patients with Duchenne who have a confirmed mutation in the DMD gene that is amenable to exon 51 skipping
  • This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with EXONDYS 51.

Exondys51hcp.com   DA: 20 PA: 16 MOZ Rank: 40

SareptAssist Patient Support Program EXONDYS 51

  • SareptAssist is a patient support program designed to help your patients navigate the process of starting and staying on EXONDYS 51
  • Upon enrolling in SareptAssist, patients are assigned dedicated Case Managers, who can provide information on: Insurance benefits

Exondys51hcp.com   DA: 20 PA: 16 MOZ Rank: 41

Learn About Duchenne Causes And Symptoms EXONDYS 51

  • Duchenne muscular dystrophy is often referred to as DMD or just Duchenne and affects mostly boys
  • It is a progressive disease that causes muscle weakness that affects many parts of the body
  • Learn the common symptoms and the underlying cause behind this rare condition and why informed decision-making at the earliest stages is so critical.

Exondys51.com   DA: 17 PA: 15 MOZ Rank: 38

BILLING & CODING GUIDE

  • 7 Please see the Important Safety Information on Page 2 and the accompanying full Prescribing Information for EXONDYS345 (eteplirsen)
  • CODING The following pages contain appropriate codes and …

Exondys51hcp.com   DA: 20 PA: 50 MOZ Rank: 77

EXONDYS 51 INFUSION ORDER

  • Title: Exondys51 Infusion Order Form - Orsini Subject: View the specialty pharmacy services form
  • Created Date: 10/19/2016 1:41:27 PM

Uhcprovider.com   DA: 19 PA: 50 MOZ Rank: 77

Approval Of Exondys 51 To Treat DMD Opposed By European

  • The Committee for Medicinal Products for Human Use (CHMP) — part of the European Medicines Agency (EMA) — is recommending against Exondys 51 (eteplirsen) as a therapy for Duchenne muscular dystrophy (DMD), Sarepta Therapeutics announced

Musculardystrophynews.com   DA: 25 PA: 50 MOZ Rank: 84

Exondys-51™ (eteplirsen)

  • ©2016 Health New England, Inc
  • Page 1 of 3 This HNE clinical criteria is only a screening tool
  • It is not for final clinical or payment decisions.

Specialtydrug.magellanprovider.com   DA: 34 PA: 26 MOZ Rank: 70

Exondys 51 (eteplirsen)

  • Exondys 51 (eteplirsen or AVI-4658), developed by Sarepta Therapeutics, is the first treatment approved by the U.S
  • Food and Drug Administration (FDA) for a specific group of patients with Duchenne muscular dystrophy (DMD)
  • These patients — 13% of the total Duchenne population — have gene deletions that are amenable to exon 51 skipping
  • Exondys 51 is designed to address the underlying

Musculardystrophynews.com   DA: 25 PA: 43 MOZ Rank: 79

Exondys 51 Prices, Coupons & Patient Assistance Programs

  • The cost for Exondys 51 intravenous solution (50 mg/mL) is around $1,680 for a supply of 2 milliliters, depending on the pharmacy you visit
  • Prices are for cash paying customers only and are not valid with insurance plans
  • Exondys 51 is available as a brand name drug only, a generic version is not yet available.

Drugs.com   DA: 13 PA: 23 MOZ Rank: 48

A Call To Action – Submit Evidence For Exondys-51

  • Once you have compiled your testimony, You can send your submissions to Molly Hunt and Alex Johnson at Duchenne UK, [email protected] and we will pass them onto EMA
  • The deadline for sending in your submissions is 10th of March 2017

Duchenneuk.org   DA: 18 PA: 22 MOZ Rank: 53

FDA Grants Accelerated Approval To First Drug For Duchenne

  • Food and Drug Administration today approved Exondys 51 (eteplirsen) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD)

Fda.gov   DA: 11 PA: 50 MOZ Rank: 75

Exondys 51® (Eteplirsen)

Mendell et al (2013) evaluated eteplirsen for the treatment of DMD in a small (n=12), randomized, multi- center, double- blind, placebo -controlled study, receiving weekly infusions of either placebo, eteplirsen 30 mg/kg or eteplirsen 50 mg/k g for 24

Uhcprovider.com   DA: 19 PA: 50 MOZ Rank: 84

Drug Approval Package: Exondys 51 Injection (eteplirsen)

  • Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 1-888-INFO-FDA (1-888-463-6332) Contact FDA

Accessdata.fda.gov   DA: 22 PA: 40 MOZ Rank: 78

Exondys 51 (eteplirsen) FDA Approval History

  • Exondys 51 FDA Approval History
  • FDA Approved: Yes (First approved September 19, 2016) Brand name: Exondys 51 Generic name: eteplirsen Dosage form: Injection Company: Sarepta Therapeutics Treatment for: Duchenne Muscular Dystrophy Exondys 51 (eteplirsen) is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of

Drugs.com   DA: 13 PA: 24 MOZ Rank: 54

Austin Showing Benefit In Non Ambulatory Population

  • At his clinical trial screening prior to starting Exondys51, my son attempted to stack five weighted cans, but was unable
  • Forty-eight weeks later, he succes

Youtube.com   DA: 15 PA: 6 MOZ Rank: 39

Exondys 51 Prices And Exondys 51 Coupons

  • Eteplirsen is a drug which lets dystrophin, the muscle protein missing in Duchenne muscular dystrophy, partially work
  • This medicine is used for the treatment of Duchenne muscular dystrophy in patients who have a specific gene mutation
  • Compare antisense therapeutics.

Goodrx.com   DA: 14 PA: 11 MOZ Rank: 44

Dosing Guidelines EXONDYS 51 (eteplirsen) Injection

EXAMPLE CALCULATION BASED ON A 33.5 KG PATIENT: Step 1: 33.5 kg x 30 mg/kg = 1,005 mg (rounded to next higher mL) Step 3: 21 mL ÷ 10 = two 10 mL vials + one 2 mL vial

Exondys51hcp.com   DA: 20 PA: 26 MOZ Rank: 66

A Treatment Option For Amenable Patients EXONDYS 51

  • EXONDYS 51 (eteplirsen) is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping
  • This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with EXONDYS 51.

Exondys51hcp.com   DA: 20 PA: 12 MOZ Rank: 53

Reference ID: 3987286

  • 24 hours at 2ºC to 8ºC (36ºF to 46ºF)
  • Application of a topical anesthetic cream to the infusion site prior to administration of

Accessdata.fda.gov   DA: 22 PA: 41 MOZ Rank: 85

Sarepta’s Exondys 51 Is Not Cost-effective, Nor

  • We'll e-mail you a link to set a new password
  • Please note this link is one-time use only and is valid for only 24 hours

Endpts.com   DA: 10 PA: 50 MOZ Rank: 83

Exondys 51 (Eteplirsen Injection): Uses, Dosage, Side

  • EXONDYS 51 (eteplirsen) injection is a sterile, aqueous, preservative-free, concentrated solution for dilution prior to intravenous administration
  • EXONDYS 51 is clear and colorless, and may have some opalescence
  • EXONDYS 51 is supplied in single dose vials containing 100 mg …

Rxlist.com   DA: 14 PA: 20 MOZ Rank: 58

The FDA And Sarepta: A Window Into The World Of Drug

  • The FDA and Sarepta: a window into the real world of drug regulation
  • I t is hard to discern the true state of drug regulation from the outside, but two recent decisions by the Food and Drug

Statnews.com   DA: 16 PA: 50 MOZ Rank: 91

Exondys-51 Intravenous: Uses, Side Effects, Interactions

Find patient medical information for Exondys-51 intravenous on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.

Webmd.com   DA: 13 PA: 50 MOZ Rank: 89

Documents Give Inside View Of FDA's Rejection, And

  • Documents give inside view of FDA’s rejection, and surprise approval, of Sarepta Duchenne’s drug Despite a strongly critical complete response letter - which the FDA sent in

Medcitynews.com   DA: 15 PA: 50 MOZ Rank: 92

Exondys European Medicines Agency

  • Exondys was expected to be used for treating Duchenne muscular dystrophy (DMD) in patients aged from 4 years with mutation (change) in the DMD gene that allows treatment involving 'exon 51 skipping'
  • This means that the patients' DMD gene can make a working form of the dystrophin protein when a part of the gene called exon 51 is not used.

Ema.europa.eu   DA: 17 PA: 32 MOZ Rank: 77

Additional Information NDA 206488 Exondys 51 (eteplirsen

  • Additional Information NDA 206488 Exondys 51 (eteplirsen) Approval
  • The documents linked on this page have been redacted for certain information that is exempt from disclosure under the Freedom of Information Act, 5 U.S.C
  • This includes, for example, trade secret information, confidential commercial information, predecisional

Accessdata.fda.gov   DA: 22 PA: 39 MOZ Rank: 90

Recently Analyzed

1: Farmsforsaleireland.com 4 seconds ago

2: Firstinmath.com 0 seconds ago

3: Kingscastleranch.com 3 seconds ago

4: Theangelalliance.com 1 seconds ago

5: Novaoselya.com 1 seconds ago

6: Parmalatmilk.com 3 seconds ago

7: King5.com 1 seconds ago

8: Asheboronc.com 3 seconds ago

9: Hamakuri.com 1 seconds ago

10: Exondys51.com 1 seconds ago

Tool Checker

Domain Expiry Date Updated

Expiry DateExpiry DateDomain ProviderHosting Provider
Exondys51.com 247 days leftCSC Corporate Domains, Inc.Amazon Technologies Inc.
Hamakuri.com 208 days lefteNom, LLCCloudflare, Inc.
Asheboronc.com3 years, 164 days leftNetwork Solutions, LLCThe Endurance International Group, Inc.
King5.com 308 days leftName.com, Inc.Amazon Technologies Inc.
Parmalatmilk.com 169 days lefteNom, LLCCloudflare, Inc.
Novaoselya.com 173 days leftHosting Ukraine LLCDomain Name Services
Theangelalliance.com 64 days leftGoDaddy.com, LLCGoDaddy.com, LLC
Kingscastleranch.com 334 days leftDomainPeople, Inc.Affinity Internet, Inc
Firstinmath.com4 years, 218 days leftNetwork Solutions, LLCAptum Technologies
Farmsforsaleireland.com1 year, 130 days leftGoDaddy.com, LLCSucuri

<< See All >>

.COM - 10,595,200+   .ORG - 1,117,549+   .EDU - 123,500+   .NET - 792,945+   .GOV - 30,232+   .US - 84,439+   .CA - 122,904+   .DE - 220,061+   .UK - 272,390+   .IT - 108,882+   .AU - 152,812+   .CO - 51,739+   .BIZ - 59,081+   .IO - 32,494+   .NL - 99,647+   .SG - 19,713+   .INFO - 81,589+   .IE - 26,934+   .ME - 25,076+   .FR - 98,576+   .EU - 61,372+   .RU - 165,043+   .PH - 9,511+   .INT - 1,166+   .IN - 87,021+   .ES - 38,035+   .CZ - 71,869+   .VN - 48,920+   .TV - 14,250+   .SITE - 9,829+   .RO - 37,484+   .PL - 44,520+   .PK - 10,373+   .MOBI - 4,464+   .LK - 5,507+   .CN - 66,137+   .CH - 66,914+   .AT - 31,992+  

Email Address Search | IP Address Blacklist Check | Hosting Providers | Domain Providers | Website Error Checker

© 2018 Site-Stats.org. All rights reserved. Email: [email protected]